Meridian Bioscience Stock News

CINCINNATI, Jan. 10, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report first quarte

CINCINNATI, Jan. 4, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 20

Meridian Bioscience Inc. (NASDAQ:VIVO) concluded the trading at $19.98 on Thursday, December 23 with a fall of -1.24% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $20.23 and 5Y monthly beta was reading 0.42 with its price kept floating in the … Meridian Bioscience Inc. (VIVO) Volatility Hits 4.16%: How An Investor Should Respond Read More »

Meridian Bioscience, Inc. (NASDAQ:VIVO) was the target of a large drop in short interest in November. As of November 30th, there was short interest totalling 2,340,000 shares, a drop of 24.0% from the November 15th total of 3,080,000 shares. Based on an average trading volume of 386,300 shares, the short-interest ratio is currently 6.1 days. []

When screening the market for bargain opportunities, investors may want to look for stocks whose trailing 12-month and forward price-earnings to growth (PEG) ratios are at or below 1.5 as of Dec. 13,

In last trading session, Meridian Bioscience Inc. (NASDAQ:VIVO) saw 0.39 million shares changing hands with its beta currently measuring 0.42. Companys recent per share price level of $19.60 trading at -$0.16 or -0.81% at ring of the bell on the day assigns it a market valuation of $795.96M. That closing price of VIVOs stock is Meridian Bioscience Inc. (NASDAQ:VIVO) Share Price Recovers 13.27% From Its Lows, But Can It Maintain Its Rise? Read More »

State of Alaska Department of Revenue increased its stake in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) by 5.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,626 shares of the companys stock after acquiring an additional 1,640 shares during the []

During the last session, Meridian Bioscience Inc. (NASDAQ:VIVO)s traded shares were 0.86 million, with the beta value of the company hitting 0.42. At the end of the trading day, the stocks price was $19.67, reflecting an intraday loss of -0.91% or -$0.18. The 52-week high for the VIVO share is $30.65, that puts it down A Bull Market Continues To Unfold On Meridian Bioscience Inc. (NASDAQ: VIVO), As It Continued To Rise 5.24% In Year-To-Date Read More »

CINCINNATI, Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board

Meridian Bioscience, Inc. (NASDAQ:VIVO)s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $21.40, but opened at $20.70. Meridian Bioscience shares last traded at $20.01, with a volume of 1,177 shares traded. A number of brokerages recently issued reports on VIVO. HC Wainwright upped their price objective on []

Related Stocks: VIVO ,

Zacks Investment Research downgraded shares of Meridian Bioscience (NASDAQ:VIVO) from a hold rating to a sell rating in a report published on Wednesday morning, Zacks.com reports. According to Zacks, Meridian Bioscience, Inc. is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and []